WASHINGTON — The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for ...
In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback